Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Becton, Dickinson and Co.

Clorox

Diageo

Fortis

Johnson & Johnson

Kimberly-Clark

McDonald's

McCormick

PepsiCo

Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the market decline might still have another 8%. Dividend aristocrats are down just 0.9% in this downturn, and many aristocrats are up modestly.

10 High-Yield Dividend Aristocrats That Could Be Perfect For What's Coming Next

Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

The U.S. Food and Drug Administration has approved the use of Novartis' drug to treat patients with a type of kidney disease, the health regulator's website showed on Wednesday.

US FDA approves Novartis' kidney disease drug

Viatris

Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

FOSTER CITY, Calif.--(BUSINESS WIRE)--Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer.

Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer

The company continues to deliver strong turnover growth and core margin expansion. Ongoing buyback combined with a juicy dividend yield provides downside protection. Positive contributions from newer drug launches. Novartis raised the 2024 core operating income guidance. Our buy rating is then confirmed.

Novartis: Another Beat, Another Raise

On July 18, Novartis AG released its second-quarter 2024 financial results, which were solid. The company's free cash flow was about $4.62 billion for the second quarter of 2024, up 40% year over year, primarily due to strong sales of its oncology franchise. So, Kisqali sales amounted to $717 million for the three months ended June 30, 2024, an increase of 45.4% year-on-year.

Why Novartis Deserves Your Attention After Q2 2024 Results

Novartis NYSE: NVS is the seventh largest pharmaceutical company in the world, and is based in Switzerland. The firm reported Q2 2024 financial results on Jul. 18, 2024.

Pharma Leader Beats on Earnings, But Shares Fall

Drugmaker Novartis' second-quarter results were better than expected. Profit guidance for the remainder of the year was also raised.

Why Novartis Stock Is Down Today Despite Topping Q2 Estimates

Novartis AG (NYSE:NVS ) Q2 2024 Earnings Conference Call July 18, 2024 8:00 AM ET Company Participants Sloan Simpson - Head of IR Vas Narasimhan - CEO Harry Kirsch - CFO Conference Call Participants Emily Field - Barclays Florent Cespedes - Bernstein Emmanuel Papadakis - Deutsche Bank Richard Parkes - BNP Paribas Graham Parry - Bank of America James Quigley - Goldman Sachs Mark Purcell - Morgan Stanley Richard Vosser - JPMorgan Peter Welford - Jefferies Peter Verdult - Citi Kerry Holford - Berenberg Seamus Fernandez - Guggenheim Securities Rajesh Kumar - HSBC Jo Walton - UBS Tim Anderson - Wolfe Research Operator Good morning and good afternoon, and welcome to the Novartis Q2 2024 Results Release Conference Call and Live Webcast. Please note that during the presentation all participants will be in a listen-only mode and the conference is being recorded.

Novartis AG (NVS) Q2 2024 Earnings Call Transcript

Novartis (NVS) American depositary receipts (ADRs) slipped Thursday even though the pharmaceutical giant beat second-quarter earnings expectations and raised its full-year core operating income guidance.

Novartis Falls Despite Earnings Beat, Guidance Raise

The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Novartis (NVS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Abbott Labs

Healthcare stocks to check out in the stock market right now.

2 Healthcare Stocks For Your Mid-July 2024 Watchlist

Novartis' (NVS) second-quarter earnings and sales beat estimates. Based on strong momentum, the company raises its operating income outlook for 2024.

Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View

Novartis topped Q2 views and lifted guidance. Shares eased after a four-month run.

Novartis Reports Near 40% Margin In Q2; Shares Slide

Merck

Merck's long-term prospects look strong despite a major incoming patent cliff. Novartis' diversified lineup and pipeline, solid results, and dividend record make it an excellent pick.

2 Magnificent Stocks to Buy With $500

Key growth drivers from the quarter included Entresto and Kesimpta drugs

Novartis lifts guidance again as demand climbs for top drugs

Swiss drugmaker Novartis raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions of drugs including heart failure treatment Entresto and Kesimpta for multiple sclerosis.

Novartis raises 2024 profit guidance for second time

Ad hoc announcement pursuant to Art. 53 LR Q2 net sales grew +11% (cc 1 , +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+28% cc), Kesimpta (+65% cc), Cosentyx (+22% cc), Kisqali (+50% cc), Leqvio (+134% cc) and Pluvicto (+44% cc) Core operating income margin 39.6%, +270 basis points (cc), mainly driven by higher net sales Q2 operating income grew +47% (cc, +43% USD) and net income up +49% (cc, +43% USD) Q2 core EPS grew +21% (cc, +17% USD) to USD 1.97 Q2 free cash flow 1 of USD 4.6 billion (+40% USD) driven by higher net cash flows from operating activities H1 sales up +11% (cc, +9% USD) and core operating income up +21% (cc, +16% USD) Q2 selected innovation milestones: Fabhalta (iptacopan) received EU, Japan and China approval for the treatment of PNH Lutathera approved by FDA for pediatric GEP-NET patients (≥12 years) Scemblix filing for 1L CML accepted by FDA; received Breakthrough Therapy designation Atrasentan FDA filing accepted for the treatment of adult patients with IgAN Kisqali NATALEE updated data showed continued clinical benefit with median follow-up ~4 years Full-year 2024 guidance raised for core operating income based on strong momentum 2 Net sales expected to grow high-single to low double-digit (unchanged) Core operating income expected to grow mid- to high teens (from low double-digit to mid-teens) Basel, July 18, 2024 – commenting on Q2 2024 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered a strong Q2, with net sales up 11% and core operating income margin approaching 40%.

Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance

Gigacloud Tech

iShares International Select Dividend ETF

U.S. stock indices have reached new highs, driven by strong corporate earnings, especially in technology. Meanwhile, many non-U.S. stocks have lagged so far in 2024.

3 Global Stocks to Buy to Escape the Volatility on Wall Street

Novartis AG will report second quarter results this week. The company should report another strong quarter, with growth led by key products such as Entresto, Kesimpta, Kisqali, Cosentyx, and Leqvio. I expect a modest revenue and EPS beat, with NVS maintaining the full-year guidance for both revenues and core operating income.

Novartis Q2 Earnings Preview: Positive Fundamental Trends Should Continue

Gilead Sciences

HCA Healthcare

Medtronic

Pfizer

Tenet Healthcare

Over the years, especially the past three, I have become more cautious about the technology sector's blatant overvaluation. Nevertheless, it is difficult to ignore the capabilities of companies such as Nvidia (NASDAQ: NVDA ) and their innovative solutions for AI.

The 7 Most Undervalued Healthcare Stocks to Buy in July 2024

Recursion Pharmaceuticals

While the pairing of artificial intelligence and healthcare may sound like something straight out of a science fiction movie, there are several avenues through which the high-speed data processing offered by AI can improve patient outcomes. From more precise diagnosis to pandemic modeling, the large-scale algorithmic models we call AI can help the world of medicine immensely.

3 Healthcare Stocks Injecting AI for Big Gains

Community Bank System

Cullen/Frost Bankers

Chevron

Altria

National Fuel Gas

Old Republic International

Polaris

Target

Stocks keep setting record highs, with valuations becoming steadily more challenging. But even at record highs, there are plenty of blue-chip bargains to buy. Free cash flow yield is a gold standard of valuation. It combines yield and quality and, if combined with growth, creates the ultimate PEG ratio, popularized by Peter Lynch. This article highlights 10 high-yield dividend aristocrats with the lowest PEG ratios, 6X better than the aristocrats and 3X better than US stocks.

10 Dividend Aristocrat Bargain Buys: High Yields And Low PEG Ratios

GlaxoSmithKline

Novo Nordisk

Undervalued pharma stocks can make good investments, whether during times of a booming economy or a faltering one. That is because people will still need medications and healthcare services regardless of the ongoing economic conditions.

The 3 Most Undervalued Pharma Stocks to Buy in July 2024

News for Novartis Stock (NVS)